CluenexStryker Corporation SYK
Stryker Corporation scores good on business quality (6.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Stryker Corporation does
Stryker sells orthopedic implants, medical instruments, and surgical technology to hospitals and physicians, generating steady revenue from equipment purchases and recurring service contracts.
- What it does best
Stryker dominates hospital surgical suites through deep product integration, posting an operating margin of 23.8% that outpaces Abbott's 17.1% and anchors long-term customer lock-in.
- The main risk
Supply chain vulnerabilities and cost inflation threaten hospital capital budgets, risking margin compression across its core hardware segments if hospital spending slows.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins at 23.8% and FCF margins at 18.2% show stable profitability, yielding better returns as production scales.
Switching costs protect its hospital relationships, backed by an operating margin sitting in the top quartile at the 74th sector percentile.
Revenue grew 11.2% to $25.8B, continuing a steady acceleration from prior years driven by core product demand.
Interest coverage sits at 6.9x alongside $11.8B of net debt, supported by $4.7B in free cash flow: overall, the balance sheet is softening.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 insider bought $27K on the open market. 3 sold $118.2M outside pre-planned sales.
Our sealed record on SYK
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Stryker Corporation scores good on the Cluenex quality check (6.3 of 10), measured against its own industry. Profitability is fair, moat fair, growth steady and financial health fair.
In the last 90 days of SEC Form 4 filings: 1 insider bought $27K on the open market. 3 sold $118.2M outside pre-planned sales.
Oct 29, 2026, after the close.
See SYK today
- Today's verdict on SYK, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Stryker Corporation (SYK)”, https://cluenex.com/stocks/syk/, data as of Oct 10, 2026.